TNGX logo

Tango Therapeutics, Inc. (TNGX) Cash From Operations

Annual CFO:

-$131.50M-$13.52M(-11.46%)
December 31, 2024

Summary

  • As of today, TNGX annual cash from operations is -$131.50 million, with the most recent change of -$13.52 million (-11.46%) on December 31, 2024.
  • During the last 3 years, TNGX annual cash from operations has fallen by -$71.97 million (-120.91%).
  • TNGX annual cash from operations is now -287.66% below its all-time high of $70.07 million, reached on December 31, 2020.

Performance

TNGX Cash From Operations Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherTNGXcash flow metrics

Quarterly CFO:

-$30.95M+$5.57M(+15.24%)
September 30, 2025

Summary

  • As of today, TNGX quarterly cash from operations is -$30.95 million, with the most recent change of +$5.57 million (+15.24%) on September 30, 2025.
  • Over the past year, TNGX quarterly cash from operations has increased by +$2.44 million (+7.30%).
  • TNGX quarterly cash from operations is now -135.12% below its all-time high of $88.14 million, reached on September 30, 2020.

Performance

TNGX Quarterly Cash From Operations Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherTNGXcash flow metrics

TTM CFO:

-$145.81M+$2.44M(+1.64%)
September 30, 2025

Summary

  • As of today, TNGX TTM cash from operations is -$145.81 million, with the most recent change of +$2.44 million (+1.64%) on September 30, 2025.
  • Over the past year, TNGX TTM cash from operations has dropped by -$23.49 million (-19.21%).
  • TNGX TTM cash from operations is now -265.44% below its all-time high of $88.14 million, reached on September 30, 2020.

Performance

TNGX TTM Cash From Operations Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherTNGXcash flow metrics

Cash From Operations Formula

CFO = Net Income + Non Cash Expenses + Changes In Working Capital

TNGX Cash From Operations Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1Y1 Year-11.5%+7.3%-19.2%
3Y3 Years-120.9%-57.8%-49.2%
5Y5 Years-287.7%-135.1%-265.4%

TNGX Cash From Operations Highs & Lows

PeriodPeriodAnnual vs HighAnnual vs HighAnnual vs LowAnnual vs LowQuarter. vs HighQuarter. vs HighQuarter. vs LowQuarter. vs LowTTM vs HighTTM vs HighTTM vs LowTTM vs Low
3Y3-Year-120.9%at low-57.8%+25.8%-49.2%+1.6%
5Y5-Year-287.7%at low-135.1%+25.8%-265.4%+1.6%
All-TimeAll-Time-287.7%at low-135.1%+25.8%-265.4%+1.6%

TNGX Cash From Operations History

DateAnnualQuarterlyTTM
Sep 2025
-
-$30.95M(+15.2%)
-$145.81M(+1.6%)
Jun 2025
-
-$36.52M(+12.4%)
-$148.25M(-9.5%)
Mar 2025
-
-$41.70M(-13.8%)
-$135.34M(-2.9%)
Dec 2024
-$131.50M(-11.5%)
-$36.65M(-9.8%)
-$131.50M(-7.5%)
Sep 2024
-
-$33.39M(-41.4%)
-$122.32M(-1.9%)
Jun 2024
-
-$23.61M(+37.6%)
-$120.07M(+0.7%)
Mar 2024
-
-$37.86M(-37.8%)
-$120.93M(-2.5%)
Dec 2023
-$117.98M
-$27.47M(+11.8%)
-$117.98M(+0.7%)
Sep 2023
-
-$31.14M(-27.2%)
-$118.78M(-10.7%)
Jun 2023
-
-$24.47M(+29.9%)
-$107.26M(+6.2%)
DateAnnualQuarterlyTTM
Mar 2023
-
-$34.91M(-23.5%)
-$114.32M(-4.8%)
Dec 2022
-$109.08M(-83.2%)
-$28.27M(-44.1%)
-$109.08M(-11.6%)
Sep 2022
-
-$19.61M(+37.8%)
-$97.72M(+1.9%)
Jun 2022
-
-$31.54M(-6.3%)
-$99.60M(-31.8%)
Mar 2022
-
-$29.66M(-75.5%)
-$75.58M(-27.0%)
Dec 2021
-$59.53M(-184.9%)
-$16.90M(+21.4%)
-$59.53M(+1.9%)
Sep 2021
-
-$21.49M(-185.9%)
-$60.69M(-224.0%)
Jun 2021
-
-$7.52M(+44.8%)
$48.94M(-13.3%)
Mar 2021
-
-$13.61M(+24.6%)
$56.46M(-19.4%)
Dec 2020
$70.07M
-$18.06M(-120.5%)
$70.07M(-20.5%)
Sep 2020
-
$88.14M
$88.14M

FAQ

  • What is Tango Therapeutics, Inc. annual cash from operations?
  • What is the all-time high annual cash from operations for Tango Therapeutics, Inc.?
  • What is Tango Therapeutics, Inc. annual cash from operations year-on-year change?
  • What is Tango Therapeutics, Inc. quarterly cash from operations?
  • What is the all-time high quarterly cash from operations for Tango Therapeutics, Inc.?
  • What is Tango Therapeutics, Inc. quarterly cash from operations year-on-year change?
  • What is Tango Therapeutics, Inc. TTM cash from operations?
  • What is the all-time high TTM cash from operations for Tango Therapeutics, Inc.?
  • What is Tango Therapeutics, Inc. TTM cash from operations year-on-year change?

What is Tango Therapeutics, Inc. annual cash from operations?

The current annual cash from operations of TNGX is -$131.50M

What is the all-time high annual cash from operations for Tango Therapeutics, Inc.?

Tango Therapeutics, Inc. all-time high annual cash from operations is $70.07M

What is Tango Therapeutics, Inc. annual cash from operations year-on-year change?

Over the past year, TNGX annual cash from operations has changed by -$13.52M (-11.46%)

What is Tango Therapeutics, Inc. quarterly cash from operations?

The current quarterly cash from operations of TNGX is -$30.95M

What is the all-time high quarterly cash from operations for Tango Therapeutics, Inc.?

Tango Therapeutics, Inc. all-time high quarterly cash from operations is $88.14M

What is Tango Therapeutics, Inc. quarterly cash from operations year-on-year change?

Over the past year, TNGX quarterly cash from operations has changed by +$2.44M (+7.30%)

What is Tango Therapeutics, Inc. TTM cash from operations?

The current TTM cash from operations of TNGX is -$145.81M

What is the all-time high TTM cash from operations for Tango Therapeutics, Inc.?

Tango Therapeutics, Inc. all-time high TTM cash from operations is $88.14M

What is Tango Therapeutics, Inc. TTM cash from operations year-on-year change?

Over the past year, TNGX TTM cash from operations has changed by -$23.49M (-19.21%)
On this page